News Agency
Men's Weekly

280Bio doses first patient in Phase I clinical trial of TEB-17231, an oral pan-RAS inhibitor in patients with advanced cancers harboring mutations in KRAS, HRAS, or NRAS

  • Written by PR Newswire

SOUTH SAN FRANCISCO, Calif., Dec. 1, 2023 /PRNewswire/ -- 280Bio, Inc., a clinical stage biotechnology company focused on the development of precision oncology medicines, today announced that the first patient was treated with TEB-17231 (YL-17231), a small molecule inhibitor of RAS signaling. 280Bio is a wholly owned subsidiary of Shanghai Yingli...

Read more: 280Bio doses first patient in Phase I clinical trial of TEB-17231, an oral pan-RAS inhibitor in...

Improving Internal Feedback Loops Through CMS-Based Commenting and Versioning

Collaboration is essential for successful digital content creation. Unfortunately, in many companies, the feedback mechanism between marketing, design, product and development functions is less than cohesive. For example, feedback is left in email chains, instant chat messages, or within locked... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion